Adaptive Immunotherapy Dosing Requires Prospective Trials to Establish Clinical Benefit
A structured review outlines requirements for testing whether adaptive cancer immunotherapy dosing preserves efficacy while reducing toxicity.
A structured review outlines requirements for testing whether adaptive cancer immunotherapy dosing preserves efficacy while reducing toxicity.
Researchers have developed a blood-testing approach that analyzes circulating chromatin fragments to monitor tumor burden and identify molecular subtypes in ...
In a multicenter observational case-control study, a serum microRNA ensemble model achieved an area under the curve of 0.875 for ...
A study in transgenic mice reveals that osteosarcoma driven by Fos overexpression causes a cachexia-like loss of adipose tissue that ...
Integrating three-dimensional spatial topology features from baseline PET/CT with volumetric burden metrics significantly improves two-year progression-free survival risk stratification in ...
A retrospective study of 109 patients finds that CD19-directed CAR T-cell therapy reduces nodal and extranodal lymphoma tumors to a ...
CA 15-3 is an epitope of the MUC1 glycoprotein. MUC1 is a transmembrane mucosa-associated glycoprotein and contains a large extracellular ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.